Home > Insider Trading > Filing (0000899243-15-004077)

Filing Details

Accession Number:: 0000899243-15-004077
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2015-08-26 18:56:29
Reporting Period:: 2015-08-21

Filing Date:: 2015-08-26
Accepted Time:: 2015-08-26 18:56:29
Original Submission Date:: 2015-08-24
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1014739	Bioscrip Inc.	BIOS	Retail-Drug Stores And Proprietary Stores (5912)	050489664

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1356974	P L Partners Capital Coliseum	Metro Center 1 Station Place, 7Th Floor, Stamford CT 06902	Yes	No	Yes	No
1409585	Coliseum Capital, Llc	Metro Center 1 Station Place, 7Th Floor, Stamford CT 06902	Yes	No	Yes	No
1409751	Coliseum Capital Management, Llc	Metro Center 1 Station Place, 7Th Floor South Stamford CT 06902	Yes	No	Yes	No
1430708	S Christopher Shackelton	Metro Center 1 Station Place, 7Th Floor, Stamford CT 06902	Yes	No	Yes	No
1454123	Adam Gray	Metro Center 1 Station Place, 7Th Floor, Stamford CT 06902	Yes	No	Yes	No
1567187	Coliseum Capital Partners Ii, L.p.	Metro Center 1 Station Place, 7Th Floor, Stamford CT 06902	Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-08-21	397,900	$1.82	632,907	No	4	P	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnotes

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.76 to $1.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These securities are held directly by (a) Coliseum Capital Partners, L.P. ("CCP"), an investment limited partnership of which Coliseum Capital, LLC, a Delaware limited liability company ("CC"), is general partner and for which Coliseum Capital Management, LLC, a Delaware limited liability company ("CCM"), serves as investment adviser, (b) Coliseum Capital Partners II, L.P. ("CCP2" and, together with CCP, the "Funds"), an investment limited partnership of which CC is general partner and for which CCM serves as investment adviser, and (c) a separate account investment advisory client of CCM (the "Separate Account").
Christopher Shackelton ("Shackelton") and Adam Gray ("Gray") are managers of and have an ownership interest in each of CCM and CC and may be deemed to have an indirect pecuniary interest in the shares held by the Funds and the Separate Account due to CCM's right to receive performance-related fees from the Separate Account and CC's right to receive performance-related fees from the Funds. Each of Shackelton, Gray, CCP, CCP2, the Separate Account, CC and CCM disclaims beneficial ownership of these securities except to the extent of that person's pecuniary interest therein.
Following the transactions reported herein, CCP, CCP2 and the Separate Account directly owned 380,186, 98,739 and 153,982 shares of common stock, respectively.
The transaction is not new, but is being reported again to gain access to the system. The amount of shares of common stock directly owned by CCP, CCP2 and the Separate Account following the transactions reported on August 24, 2015 was originally reported as 380,186, 119,364 and 133,357 shares, respectively. This amendment to Form 4 reflects the correct amount of shares of common stock directly owned by CCP, CCP2 and the Separate Account following the transactions reported on August 24, 2015 as 380,186, 98,739 and 153,982 shares, respectively.